MESO FY 2022 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+37.0% YoY

Gross Profit

-$53M-522.6% margin

Operating Income

-$81M-789.1% margin

Net Income

-$91M-894.6% margin

EPS (Diluted)

$-1.30

Cash Flow

Operating Cash Flow

-$66M

Free Cash Flow

-$66M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$662M

Total Liabilities

$165M

Stockholders' Equity

$497M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$7M	+37.0%
Gross Profit	-$53M	-$78M	+31.8%
Operating Income	-$81M	-$109M	+26.1%
Net Income	-$91M	-$99M	+7.6%